BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 3. F1000Res. 2018 Nov 20;7:F1000 Faculty Rev-1826. doi: 10.12688/f1000research.15953.1. eCollection 2018. Chondrosarcoma: biology, genetics, and epigenetics. Chow WA(1). Author information: (1)Department of Medical Oncology & Therapeutics Research, City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. Chondrosarcomas constitute a heterogeneous group of primary bone cancers characterized by hyaline cartilaginous neoplastic tissue. They are the second most common primary bone malignancy. The vast majority of chondrosarcomas are conventional chondrosarcomas, and most conventional chondrosarcomas are low- to intermediate-grade tumors (grade 1 or 2) which have indolent clinical behavior and low metastatic potential. Recurrence augurs a poor prognosis, as conventional chondrosarcomas are both radiation and chemotherapy resistant. Recent discoveries in the biology, genetics, and epigenetics of conventional chondrosarcomas have significantly advanced our understanding of the pathobiology of these tumors and offer insight into potential therapeutic targets. DOI: 10.12688/f1000research.15953.1 PMCID: PMC6248264